Immunogenicity of glycine nanoparticles containing a chimeric antigen as Brucella vaccine candidate
10.7774/cevr.2021.10.1.35
- Author:
Ghazal KAREVAN
1
;
Kazem AHMADI
;
Ramezan Ali TAHERI
;
Mahdi FASIHI-RAMANDI
Author Information
1. Department of Biology, Nourdanesh Institute of Higher Education, Meymeh, Iran
- Publication Type:Original article
- From:Clinical and Experimental Vaccine Research
2021;10(1):35-43
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Brucellosis as a worldwide zoonotic illness affect domestic animals and humans doesn’t have any vaccine for the prevention of infection in humans yet. The aim of this study was to evaluate the specific immune response following the administration of glycine nanoparticles as adjuvant and delivery system of a chimeric antigen contained trigger factor, Omp31, and Bp26 in murine model.
Materials and Methods:The chimeric antigen of Brucella was cloned and expressed in Escherichia coli (E. coli) BL21 (DE3). Purification and characterization of recombinant protein was conducted through Ni-NTA (nickel-nitrilotriacetic acid) agarose, SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), and Western blot. Nanoparticle characteristics including morphology, particle size distribution, zeta potential, protein retention rate, and release rate were measured in vitro. Subsequently, nanoparticle contained antigen was administered to mice and blood sample was taken to measured the antibody level.
Results:The protein retention in the nanoparticles was successfully done and the nanoparticle characteristics were appropriate. The average size of glycine particles containing antigen was about 174 nm, and the absorption of protein was approximately 61.27% of the initial value, with a release rate of approximately 70% after 8 hours. Enzyme-linked immunosorbent assay result proved that the immunized sera of mice which were administered with nano-formula contains high levels of antibodies (immunoglobulin G) against recombinant chimeric antigen and also a high level of mucosal antibody (immunoglobulin A) in the oral group, which showed a desirable immunity against Brucella.
Conclusion:The results showed that chimeric antigen-loaded glycine nanoparticles can act as a vaccine candidate for inducing the cellular and humoral immune response against brucellosis.
